Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 14/20 | 0.63 |
| ▸ | KCNQ2 | O43526 | 14/20 | 0.63 |
| ▸ | KCNE1 | P15382 | 11/20 | 0.58 |
| ▸ | KCNQ1 | P51787 | 11/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436172 | 0.85 | KCNQ3 (0.67) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL30568974 | 0.82 | KCNQ3 (0.64) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL6361424 | 0.82 | KCNQ3 (0.64) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL265831 | 0.82 | KCNQ3 (0.72) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL203109 | 0.81 | KCNQ3 (0.54) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL11728090 | 0.79 | RAB9A (0.52) | RAB9ASMN1; SMN2PTPN1PTPN11 | |
| SCHEMBL16785423 | 0.79 | KCNQ3 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5629234 | 0.79 | KCNQ3 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5629229 | 0.79 | KCNQ3 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5217004 | 0.77 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | KCNQ3 3423/4885KCNQ2 2791/4885KCNE1 2169/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | KCNQ3 657/4885KCNQ2 399/4885KCNE1 524/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | KCNQ3 548/4885KCNQ2 603/4885KCNE1 310/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | KCNQ3 709/4885KCNQ2 871/4885KCNE1 640/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | KCNQ3 709/4885KCNQ2 871/4885KCNE1 640/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | KCNQ3 709/4885KCNQ2 871/4885KCNE1 640/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | KCNQ3 421/4885KCNQ2 576/4885KCNE1 621/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | KCNQ3 171/4885KCNQ2 238/4885KCNE1 347/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | KCNQ3 709/4885KCNQ2 871/4885KCNE1 640/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | KCNQ3 3423/4885KCNQ2 2791/4885KCNE1 2169/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | KCNQ3 517/4885KCNQ2 672/4885KCNE1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.